Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Jiangsu Recbio Technology Co., Ltd. Class H (2179) Stock Price & Analysis

1 Followers

2179 Stock Chart & Stats

HK$3.90HK$0.00(0.00%)
At close: 4:00 PM GMT+8
HK$3.5HK$4HK$4.5HK$5Aug 6Aug 25Sep 17Sep 23Oct 7Oct 20Nov 2
Day’s Range
HKD 3.90 - HKD 3.90
52-Week Range
HKD 1.00 - HKD 6.70
Previous Close
HKD 3.90
Volume
N/A
Average Volume (3M)
5,517
Market Cap
HKD 2.43B
Enterprise Value
HKD 3.46B
Total Cash (Recent Filing)
HKD 187.51M
Total Debt (Recent Filing)
HKD 672.99M
Price to Earnings (P/E)
―
Beta
0.54
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Leverage

The reduction in debt relative to equity improves financial flexibility and lowers balance-sheet risk compared with the prior year. Although leverage remains meaningful, this direction of change gives the company a stronger foundation to manage development spending and pursue commercialization over the next several quarters.

Integrated Vaccine Development Capabilities

Control across discovery, clinical development, regulatory registration and manufacturing scale-up can support better coordination from research through commercialization. This integrated operating model may help retain more value from successful programs and build capabilities that remain useful across multiple vaccine candidates.

Multiple Biotech Revenue Routes

The stated model provides several potential routes to monetize vaccine and biologics capabilities, including product commercialization, licensing, collaborations and platform services. This creates strategic optionality beyond a single product launch, although the pack does not establish the materiality of each stream.

Bears Say

Sharp Revenue Contraction

A steep year-over-year revenue decline indicates that commercialization has not yet developed into a stable, repeatable growth engine. Continued volatility makes operating planning more difficult, limits internal funding capacity and increases dependence on future product progress or external financing.

Persistent Deep Losses

Negative gross profit alongside large operating and net losses points to weak current earnings quality and limited evidence of sustainable unit economics. Without clearer margin improvement, future revenue growth may not translate efficiently into self-funded operations or durable shareholder value.

Ongoing Cash Burn

Recurring negative operating and free cash flow means the business continues consuming cash to fund operations and investment rather than generating internal liquidity. Persistent burn can constrain development plans and leave the company reliant on external funding while losses remain substantial.

Jiangsu Recbio Technology Co., Ltd. Class H News

2179 FAQ

What was Jiangsu Recbio Technology Co., Ltd. Class H’s price range in the past 12 months?
Jiangsu Recbio Technology Co., Ltd. Class H lowest stock price was HK$1.00 and its highest was HK$6.70 in the past 12 months.
What is Jiangsu Recbio Technology Co., Ltd. Class H’s market cap?
Jiangsu Recbio Technology Co., Ltd. Class H’s market cap is HK$2.43B.
When is Jiangsu Recbio Technology Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Jiangsu Recbio Technology Co., Ltd. Class H’s earnings last quarter?
Jiangsu Recbio Technology Co., Ltd. Class H released its earnings results on Aug 19, 2026. The company reported -HK$0.4 earnings per share for the quarter.
Is Jiangsu Recbio Technology Co., Ltd. Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Jiangsu Recbio Technology Co., Ltd. Class H pay dividends?
Jiangsu Recbio Technology Co., Ltd. Class H does not currently pay dividends.
What is Jiangsu Recbio Technology Co., Ltd. Class H’s EPS estimate?
Jiangsu Recbio Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jiangsu Recbio Technology Co., Ltd. Class H have?
Jiangsu Recbio Technology Co., Ltd. Class H has 458,092,160 shares outstanding.
What happened to Jiangsu Recbio Technology Co., Ltd. Class H’s price movement after its last earnings report?
Jiangsu Recbio Technology Co., Ltd. Class H reported an EPS of -HK$0.4 in its last earnings report. Following the earnings report the stock price went down -2.057%.
Which hedge fund is a major shareholder of Jiangsu Recbio Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2179
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology